Rezolute (RZLT) announced the appointment of Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. joining the Company, he served as a Vice President at Cytokinetics (CYTK) and Ultragenyx (RARE)
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute Appoints New Chief Commercial Officer
- Rezolute Completes Enrollment for Phase 3 sunRIZE Study
- Rezolute files to sell 1.3M shares of common stock for holders
- Promising Future for Rezolute’s Ersodetug in Treating Congenital Hyperinsulinism: Analyst Recommends Buy
- Positive Buy Rating for Rezolute Driven by Promising Phase 3 Study Results and Strong Efficacy Potential